In-Body CAR-T: a new shot at fighting blood cancers?

NCT ID NCT07511426

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. The trial will enroll about 30 adults and focus first on safety, checking for side effects and how well the treatment is tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: U96 (a gene therapy that creates CAR-T cells inside the body to target CD19 on cancer cells)
What this could lead to: If it works, this could offer a new treatment option for patients with hard-to-treat B-cell cancers, potentially reducing the need for complex lab-made CAR-T cells.
What could go wrong: This is a very early Phase 1 trial with only 30 patients, so it is too soon to know if it is safe or effective. There are risks of serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE B LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm Leukemia, B-Cell lymphoma precursor B-cell acute lymphoblastic leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY B CELL LEUKEMIA AND LYMPHOMA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.